• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Dey Svetlana

    3/24/23 1:48:27 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care
    Get the next $BJDX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Dey Svetlana

    (Last) (First) (Middle)
    C/O BLUEJAY DIAGNOSTICS, INC.
    360 MASSACHUSETTS AVENUE, SUITE 203

    (Street)
    ACTON MA 01720

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Bluejay Diagnostics, Inc. [ BJDX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/24/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/24/2023 A 10,000 A $0.44 47,500 D
    Common Stock 4,091,356 I Held by Lana Management & Business Research International, LLC(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Lana Management & Business Research International, LLC is an entity owned by Mr. Indranil Dey and Ms. Svetlana Dey. Ms. Dey has voting and dispositive power over the shares held by such entity.
    /s/ Svetlana Dey 03/24/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BJDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BJDX

    DatePrice TargetRatingAnalyst
    1/12/2022$10.00Buy
    Dawson James
    More analyst ratings

    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on Bluejay Diagnostics with a new price target

      Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00

      1/12/22 9:00:51 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

      ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: SYMON Clinical Program Update: The Company has initiated its pivotal SYMON-II clinical study, following the successful completion of the SYMON-I pilot study, for which a primary analysis highlighted that IL-6 levels within 24 hours of ICU admission may predict sepsis patient mortality out to 28 days. Currently, the Company is collecting, freezing and biobanking samples, w

      6/3/25 4:05:00 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

      ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit (ICU), will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity. "Early use of IL-6 in sepsis and septic shock pat

      4/15/25 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

      ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting

      4/7/25 5:21:14 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

      ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.

      3/28/22 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

      ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa

      1/5/22 8:15:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Scally Frances P

      3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      10/11/23 7:21:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BJDX
    SEC Filings

    See more

    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 5:49:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

      SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 3:54:54 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      7/3/24 4:01:01 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/28/25 5:18:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Bluejay Diagnostics Inc.

      DEF 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/16/25 5:00:34 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bluejay Diagnostics Inc.

      10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/13/25 4:01:45 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care